MedTrace Logo

Contribution of PET/MRI in Locally Advanced Cervical Cancer (ATICC)

NCT06083103 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 50

Last updated 2026-02-02

No results posted yet for this study

Summary

\[18 F\]fluorodeoxyglucose (18F-FDG) positron emission tomography-magnetic resonance imaging (PET/MRI) is a new hybrid imaging tool that has recently arrived in oncology, and is particularly promising. Its usefulness seems obvious in certain tumor types, but its place in the staging of cervical cancers has never been explored in a prospective trial to our knowledge.

Previously, a comparative retrospective study from 2009 found a better sensitivity of PET fused to diagnostic MRI images compared to PET/CT (positron emission tomography/computed tomography) in the detection of metastatic lymph nodes (54 and 44% respectively). It was an a posteriori fusion of images, from images acquired by PET-CT.

Conditions

Interventions

DIAGNOSTIC_TEST

18-FDG PET-MRI

For this trial, 18-FDG PET-MRI will be conducted directly after PET-CT using a single dose of radiotracer

Sponsors & Collaborators

  • Centre Paul Strauss

    lead OTHER

Principal Investigators

  • Éric OUVRARD, MD · Institut de cancérologie Strasbourg Europe

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-10-12
Primary Completion
2026-09-11
Completion
2026-09-11

Countries

  • France

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06083103 on ClinicalTrials.gov